Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Apellis Pharmaceuticals Inc (APLS) today and set a price target of $40. The company’s shares opened today at $15.44.
According to TipRanks.com, Nadeau is a 4-star analyst with an average return of 6.5% and a 45.8% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Rhythm Pharmaceuticals Inc, and Allogene Therapeutics Inc.
Apellis Pharmaceuticals Inc has an analyst consensus of Strong Buy, with a price target consensus of $41.75, a 170.4% upside from current levels. In a report released today, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $53 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $32 and a one-year low of $11.45. Currently, Apellis Pharmaceuticals Inc has an average volume of 263.2K.
Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of APLS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product.
